Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $13.50

by · The Markets Daily

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have earned an average rating of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $13.50.

A number of analysts have weighed in on AMRX shares. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Piper Sandler reiterated an “overweight” rating and issued a $13.00 target price (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Barclays began coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 price target on the stock.

Get Our Latest Research Report on AMRX

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $12.60 on Thursday. The firm has a fifty day moving average price of $11.90 and a 200-day moving average price of $10.06. Amneal Pharmaceuticals has a 1 year low of $6.68 and a 1 year high of $13.01. The stock has a market cap of $3.96 billion, a PE ratio of 630.32 and a beta of 1.36.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The firm had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, research analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Nikita Shah sold 131,856 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the sale, the executive vice president directly owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This trade represents a 47.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ted C. Nark sold 50,000 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $11.72, for a total transaction of $586,000.00. Following the sale, the director directly owned 291,029 shares in the company, valued at approximately $3,410,859.88. The trade was a 14.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 231,856 shares of company stock valued at $2,743,724 over the last 90 days. 26.56% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Amneal Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company’s stock worth $98,000 after purchasing an additional 1,735 shares during the last quarter. Comerica Bank grew its stake in Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Rafferty Asset Management LLC increased its stake in shares of Amneal Pharmaceuticals by 22.0% during the second quarter. Rafferty Asset Management LLC now owns 16,984 shares of the company’s stock worth $137,000 after buying an additional 3,066 shares during the period. Exchange Traded Concepts LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $31,000. Finally, SG Americas Securities LLC increased its holdings in Amneal Pharmaceuticals by 3.5% in the second quarter. SG Americas Securities LLC now owns 99,129 shares of the company’s stock valued at $802,000 after buying an additional 3,368 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Read More